AAVantgarde

We're #hiring a new Director/ Associate Director, Clinical Quality Assurance in United Kingdom. Apply today or share this post with your network.

We're #hiring a new Associate Director, Surgical/ Medical Science Liaison - Ophthalmology in United States. Apply today or share this post with your network.

Here is what Cheryl Kuai, Ph.D, CFA, Ph.D, CFA, Managing Director at Sixty Degree Capital had to say about our $141m Series B round: “We’re proud to support AAVantgarde in their mission to deliver transformative therapies for patients living with progressive vision loss. Their strong scientific foundation and potential to make a meaningful impact for patients align closely with Sixty Degree Capital’s mission to address diseases with high unmet medical needs.” Thank you Cheryl, and the team at Sixty Degree Capital, for your support. #InheritedRetinalDiseases #Stargardt #Usher1b #AAVantgarde #SeriesB

We're #hiring a new Senior/ Accountant in London, England. Apply today or share this post with your network.

Today, we'd like to thank Julian Zachmann at ATHOS for his support in our $141m Series B fundraise. In his words: "AAVantgarde’s platform could overcome limitations of current AAV technologies and reach underserved patients. Early clinical data suggests AAVantgarde may develop best-in-class treatments for Usher-1B and Stargardt’s disease. We’re proud to join this mission to bring next‑generation genetic medicines to patients in need and help prevent vision loss." #InheritedRetinalDiseases #AAVantgarde #SeriesB #Biotech

AAVantgarde is delighted to announce that we have closed a series B round worth $141m.   This milestone marks a significant step forward in our mission to transform eye care through our powerful gene delivery technologies.   We would like to extend our deepest gratitude to all our investors – both old and new – who made this round possible. Your support allows us to continue our work to transform the lives of patients with inherited retinal diseases for the better.   With the $141 million, we will:   Continue to develop AAVB-039, our candidate for Stargardt Disease caused by a mutation in the ABCA4 gene, completing both our observational STELLA study, and our ongoing interventional CELESTE Phase 1/2 (CELESTE) study.    Continue to develop AAVB-081, our lead candidate which aims to address retinitis pigmentosa (RP) secondary to Usher 1B due to a mutation in the MYO7A gene as it advances through its phase ½ study, LUCE-1.   For more information, please check our press release: https://lnkd.in/eFaQdpKN   The future of ophthalmology is bright – and we’re just getting started. Keep a look out for more great news from AAVantgarde. #SeriesB #AAVantgarde #Ophthalmology #Innovation #LifeSciences #IRDs

The AAVantgarde Bio team will be in Vienna next week for this year's BIO Europe event, taking place between the 3rd and the 5th of November.   We look forward to meeting partners and friends new and old - if you want to learn more about AAVantgarde's promising programs in IRDs, reach out to either our CEO, Natalia Misciattelli, or our head of corporate development, Magdalena Blanco. #BIOEUROPE2025 #BusinessDevelopment #Pharma #IRDs #RareDiseases #AAVantgarde

🌟This year's AAO in Orlando was host to the bi-annual Eyecelerator event, a day dedicated to highlighting the frontiers of ophthalmology - disruptive ongoings, investment trends and new discoveries.🌟   Among the presenters was our fantastic CEO, Natalia Misciattelli, who gave a talk on the recent progress made by AAVantgarde in its clinical trials for Usher 1B and Stargardt Disease.   We have lots of big news coming... so stay tuned for more updates from the AAVantgarde team. 👀 #AAVantgardeBio #AAO #Eyecelerator #Ophthalmology

The AAVantagarde team had an amazing - and busy - time at this year's ESGCT in Seville, Spain, with three presentations focusing on our work. First, our Stargardt Disease KO model was presented by the fantastic Ivana Trapani, a session in which she also received the ESGCT's Career Progression Award. We also got to show off our updated LUCE data during the Late Breaker session. And finally, we would like to thank Douglas Marsh, our Principle Scientist, for his hard work presenting a poster he helped create, titled: "Platform Development for a Dual AAV Therapy." Our platforms are, of course, crucial to our mission of restoring vision in patients with inherited retinal diseases. Follow us on our journey as we continue through our LUCE-1 and STELLA trials. #AAVantgarde #InheritedRetinalDiseases #ESGCT

📅 Catch us in Orlando next weekend! The AAVantgarde team is on the road again for this year's American Academy of Ophthalmology's annual meeting which is being held October 18-20. As ever, we are excited to surround ourselves in the latest cutting edge opthalmic science, and look forward to meeting friends new and old as we continue our journey of transforming the lives of patients with inherited retinal diseases.   #AAVantgarde #AAO2025 #IRD #Ushers #Stargardt